REBEL Cast - Is Pip-Tazo Harming Sepsis Patients?

In this episode of RebelCast, host Dr. Marco Propersi and guest Dr. Lynnsey Moss discuss the comparative study of piperacillin-tazobactam versus cefepime in the treatment of undifferentiated sepsis. They discuss a recent retrospective cohort study which examines 90-day mortality rates is sepsis patients treated with these antibiotics. The researchers explore the role of anti-anaerobic coverage and its potential for disrupting the gut microbiome. Key points discussed include the method of instrumental variable analysis, the validity of study findings, and a comparison with the ACORN trial. The episode concludes with a cautious stance on changing clinical practice based on these findings.

 

00:00 Introduction and Welcome

00:14 Meet Lindsey Moss

00:37 Discussion on Piptazo vs Cefepime

01:55 Research Background and ACORN Trial

03:03 Study Methodology

05:20 Study Results and Analysis

08:52 Instrumental Variable Analysis Explained

12:11 Critical Evaluation of the Study

17:44 Conclusion and Takeaways

18:36 Closing Remarks